IDEAYA Biosciences (IDYA)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.57 (-2.24%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of IDEAYA Biosciences (IDYA)
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.

Key Insights

Critical company metrics and information

  • Share Price

    $25.05

  • Market Cap

    $2.17 Billion

  • Total Outstanding Shares

    86.43 Million Shares

  • Total Employees

    124

  • Dividend

    No dividend

  • IPO Date

    May 23, 2019

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Phone Number

    650-443-6209

  • Address

    5000 shoreline ct, suite 300, South san francisco, CA, 94080

  • Homepage

    https://www.ideayabio.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow$248.62 Million
Net Cash Flow From Operating Activities$-149.68 Million
Net Cash Flow From Operating Activities, Continuing$-149.68 Million
Net Cash Flow From Investing Activities, Continuing$-417.39 Million
Net Cash Flow, Continuing$248.62 Million
Net Cash Flow From Investing Activities$-417.39 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Basic Average Shares$241.86 Million
Income Tax Expense/Benefit$0.00
Diluted Average Shares$241.86 Million
Operating Income/Loss$-224.75 Million
Research and Development$193.26 Million
Revenues$3.92 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Liabilities$40.66 Million
Noncurrent Liabilities$18.80 Million
Noncurrent Assets$307.66 Million
Accounts Receivable$20,000.00
Equity Attributable To Parent$1.18 Billion
Assets$1.24 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2025 Financhle. All Rights Reserved.